Atezolizumab Plus Bevacizumab Combination Therapy Compared to Sorafenib and Atezolizumab Monotherapies for Treatment of Unresectable or Metastatic Hepatocellular Carcinoma

7 PAGES (519 WORDS) Internal Medicine Paper

Read Download

Overview
Cite Work

Background/Aim

Sorafenib has been the historical first-line treatment of choice for unresectable or metastatic hepatocellular carcinoma (HCC) since 2007.

However, on May 29, 2020, FDA approved atezolizumab plus bevacizumab (AB) combination for HCC and gave it priority over sorafenib.

Here, we performed a systematic review evaluating the efficacy and safety of combination immunogenic chemotherapy as first-line therapy as opposed to sorafenib (S) and atezolizumab (A) monotherapies.

Read Download